Abivax reports promising ABX464 phase 2a one-year maintenanc

Abivax SA , a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, today reports... | March 10, 2022

Related Keywords

Germany , Japan , Paris , France General , France , Hungary , United Kingdom , Belgium , Italy , Poland , Spain , Hartmutj Ehrlich , William Robinson , Enregistrement Universel , Paul Emery , Division Of Immunology , Leeds Teaching Hospitals , Leeds Musculoskeletal Biomedical Research Centre , American College Of Rheumatology , Leeds Institute Of Rheumatic , Stanford University , Euronext , Euronext Paris , Versus Arthritis Professor , Leeds Teaching Hospitals Trust , Leeds Institute , Musculoskeletal Medicine , French Autorit , Des March , American College , Disease Activity Score , Abivax Stock Exchange , News , Information , Press Release , Abivax , Biotechnology , Company , Developing , Novel , Therapies , Hat , Modulate , The , Immune , System , O , Treat , Hronic , Inflammatory , Viral , End , Oday Abvx Fr0012333284 ,